drugset / Trial / NCT07484724
A Study Evaluating the Safety and Efficacy of JS212 Combination Therapy in Patients With Advanced Esophageal Squamous Cell Carcinoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This study is an open-label, multi-center phase II clinical trial aimed to evaluat the safety and preliminary efficacy of JS212 combination therapy in patients with advanced esophageal squamous cell carcinoma (ESCC).
Timeline
- Start
- 2026-04-13
- Primary completion
- 2027-06-30
- Completion
- 2028-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JS212 | Unknown | — | — |
| Subject | Toripalimab | Monoclonal antibody | — | — |
| Subject | fluorouracil | Small molecule | — | — |